FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 239 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... September 27, 2021 Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast... January 14, 2021 Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma February 4, 2019 20 years of Cancer Research UK: Celebrating our research nurses December 7, 2022 Load more HOT NEWS Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,... 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute...
